NASDAQ OMX

Karolinska Development company Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors

Dela

STOCKHOLM - September 5, 2017. Umecrine Cognition AB, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company in clinical development with a novel GABAA receptor modulator for the treatment of hepatic encephalopathy (HE) in patients with liver disease, today announces that Dr. Thomas P. Blackburn has been appointed as a new member of its Board of Directors and Senior Development Adviser.

Details from the Umecrine Cognition press release follow:
Dr. Thomas P. Blackburn brings more than 40 years of experience in the pharmaceutical and biotechnology sectors, where he has held C-level and senior management positions at major Pharmaceuticals (ICI, Beecham/SmithKline Beecham) and US biotech companies (Synaptic Pharmaceutical Corporation and Helicon Therapeutics). His extensive knowledge of pre-clinical and clinical drug development in neuroscience led to the clinical development of antidepressant/anxiolytics (Seroxat®/Paxil®), anticonvulsants, antimigraine, sleep and cognitive disorders (MCI, Alzheimer's Disease, ADHD), along with commercial strategies for positioning pharmaceutical products with U.S., European and Japanese regulatory authorities. 

Magnus Doverskog, CEO of Umecrine Cognition, said: "We are pleased to have Dr. Blackburn join the company. He is an internationally recognized neuroscientist, who has led companies, departments and project teams that have identified and developed novel therapeutics. Dr. Blackburn's expertise is in discovering innovative therapeutics and developing clinical candidates to "proof-of-concept" and commercialization."

Dr. Blackburn commented: "I am delighted to have the opportunity to bring my neuroscience and drug development expertise to Umecrine Cognition. The Company's innovative therapeutic approach of restoring GABA-ergic neurotransmission through inhibition of neurosteroid dysfunction holds great promise for the treatment of hepatic encephalopathy in liver disease and opens up several potential therapeutic opportunities for the treatment of other CNS disorders representing exciting and emerging areas of unmet clinical need and commercial opportunity."

Dr. Blackburn has authored more than 100 scientific papers, review articles, book chapters, and is currently Reviews Editor for the British Journal of Pharmacology.  He is an inventor/co-inventor on 22 patents and holds a Ph.D., D.Sc., from the University of Manchester, he is an Honorary Fellow and President Emeritus of The British Pharmacological Society, a member of the American College of Neuropsychopharmacology and Fellow of the Royal Society of Biology (FRSB). He also serves as a board member of Motac Neurosciences Ltd., a company that specializes in pre-clinical models of Parkinson's disease and neurodegeneration.

For further information, please contact:

Viktor Drvota, VD, Karolinska Development AB
Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

TO THE EDITORS

About Umecrine Cognition AB

Umecrine Cognition, a Karolinska Development (Nasdaq Stockholm: KDEV) portfolio company, is developing a potential therapy that represents a new target class relevant for several major CNS-related disorders. The primary focus is to develop a treatment for life-threatening overt hepatic encephalopathy and long-term treatment in covert hepatic encephalopathy in patients with liver disease, a growing area with high unmet medical need. The current lack of therapeutics that directly addresses the neurocognitive signs and symptoms of Hepatic Encephalopathy makes a novel treatment likely to become a major contribution for the treatment of this disorder. For more information, please visit www.umecrinecognition.com.

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying medical innovation and investing in the creation and growth of companies developing these assets into differentiated products that will make a difference to patients' lives and provide an attractive return on investment to its shareholders.

Karolinska Development has access to world-class medical innovations at leading universities and research institutes in the Nordic region, including the Karolinska Institutet. The Company aims to build companies around innovative products and technologies, supported by experienced management teams and advisers, and co-funded by specialist international life science investors, to provide the greatest chance of success.

Karolinska Development's portfolio comprises 9 companies focusing on the development of innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by a team of investment professionals with strong investment backgrounds, experienced company builders and entrepreneurs, with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 201819.4.2018 13:00Pressmeddelande

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Company will report full year 2017 financial results on Thursday, April 26, 2018. Merus' management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, April 26, 2018, to discuss the financial results and recent clinical and corporate developments. To participate in the call, please dial (877) 260-1463 (U.S.) or (706) 643-5907 (international) and reference conference ID 6184636. A live webcast will be available on the Investors page of the Company's website, http://www.merus.nl. An archived webcast replay will be available for 90 days. About Merus N.V. Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeut

SEMAFO: Construction of Boungou Mine 91% Complete19.4.2018 13:00Pressmeddelande

Commissioning Advancing to Plan MONTREAL, April 19, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) announced that construction of the Boungou Mine in Burkina Faso is 91% complete, and commissioning activities are advancing well with 10% already completed at the end of March. Since launch of commissioning at the end of February, the crushing circuit equipment and water services have been tested and commissioned. The reclaim and grinding circuits, reagent and oxygen plants are also undergoing testing. Wet commissioning began at the end of March with the Corporation pumping water from the water storage facility to the raw water tanks for the processing plant. We are still in line to achieve our first gold pour early in the third quarter of 2018. As at March 31, 2018, the following milestones had been reached: Development on budget with US$194 million of the US$231 million capital expenditure incurred Construction of the mine 91% complete Completion of 98% of structural steel and

Standard Lithium Completes Successful Gravity Geophysical Survey at Cadiz Dry Lake, California Lithium Project19.4.2018 11:30Pressmeddelande

VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that Hasbrouck Geophysics Inc. has successfully completed a large-scale gravity geophysical survey at the Company's Cadiz Dry Lake Project, in the Mojave area of California. The Cadiz Dry Lake Property is located approximately 20 km southeast of the Company's Bristol Dry Lake Property and is currently permitted for brine extraction and processing activities. The work has defined an infilled basin with a maximum depth of just over 700 m beneath the Project area. Dr. Andy Robinson, COO and President of Standard Lithium commented: "The results from this high quality geophysical survey are very encouraging. This work has defined a closed basin with infill deposits that are known to host lithium brines, based on preliminary sampling of extraction wells operated by the permitted producer. Standard Lithium's excellent relations

ConnectWise Launches Unite, Its Cloud Monitoring, Management and Billing Solution19.4.2018 10:03Pressmeddelande

IT Nation Europe keynote also reveals plans for an advanced security dashboard and growing the company's international footprint LONDON, April 19, 2018 (GLOBE NEWSWIRE) -- ConnectWise CEO Arnie Bellini told an audience of more than 350 at the company's annual IT Nation Europe conference in London that ConnectWise Unite is now available to technology teams across the globe. Unite is a cloud management solution that gives technology teams the ability to manage, monitor and bill a broad range of cloud-based solutions through a single pane of glass and in their own currency. "Technology teams typically take advantage of a broad range of cloud solutions to meet their customers' unique needs. What we've done with ConnectWise Unite is give our partners the ability to access these disparate solutions from a single pane of glass and greatly simplify the complexity that comes from dealing with the growing number of solutions they use," Bellini said. He explained that connecting the ecosystem sea

D4t4 Solutions Announces Latest Celebrus Release19.4.2018 10:00Pressmeddelande

Celebrus Advances Customer Data Platform Leadership Further with New Product Features Latest update consolidates Celebrus as enterprise CDP of choice for banking and insurance sectors Integration with Adobe Experience Cloud augments leading digital marketing platform with streaming customer data New Audience Segmentation feature enables advanced targeting of individuals even when they have left a site or app Latest connector supports creation of Custom Audiences in Google and Facebook Hadoop capabilities extended with enhanced support for Hive open-source data warehouse SUNBURY-ON-THAMES, United Kingdom, April 19, 2018 (GLOBE NEWSWIRE) -- D4t4 Solutions Plc has announced general availability for the latest release of its leading Celebrus Customer Data Platform (CDP). Continuing its commitment to creating the industry's most advanced unified system for customer data, Version 8 Update 19 delivers a host of new features that broaden the appeal of Celebrus to enterprises focused on deepeni

Leading European Media Company De Persgroep Selects Aria Systems for Digital Transformation19.4.2018 09:08Pressmeddelande

Aria's cloud billing and monetization platform will manage millions of subscriptions across dozens of media properties SAN FRANCISCO and ASSE, Belgium, April 19, 2018 (GLOBE NEWSWIRE) -- Aria Systems, the leader in helping enterprises grow subscription- and usage-based revenue, today announced that De Persgroep, the leading news media publisher in the Netherlands, Belgium and Denmark, is deploying Aria's platform to enable their digital growth strategy. With Aria the company will accelerate time to market for new products, increase subscriber growth and retention, and improve the overall customer experience. Among the publications included in this digital strategy are 18 newspapers and periodicals across the portfolios of De Persgroep Publishing, De Persgroep Nederland, and Berlingske Media. De Persgroep selected Aria's cloud-based billing and monetization platform to support the subscription management processes for all news media and magazine subscriptions. The company can now manage

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum